Cohance Lifesciences Regulatory Approval

Board Meeting Date

Cohance Lifesciences Board Meeting Date

Cohance Lifesciences will hold a board meeting on 6 November 2026 to approve Q2 and half-year results. The trading window stays closed until 9 November 2026.

Other Announcement

Cohance Lifesciences Other Announcement

Cohance Lifesciences Ltd filed its quarterly shareholding pattern under Regulation 31(1)(b), disclosing promoter and public shareholding data as of September 30, 2026.

Employee Stock Options

Cohance Lifesciences Employee Stock Options

Cohance Lifesciences Ltd. approved the grant of 2,60,194 stock options under ESOP 2026 and 6,14,594 stock options under ESOP 2023 to eligible employees.

Management Change

Cohance Lifesciences Management Change

Cohance Lifesciences appointed Mr. Abhimanyu Ojha as the new Chief Financial Officer and Key Managerial Personnel, effective October 12, 2026.

Other Announcement

Cohance Lifesciences Other Announcement

Cohance Lifesciences received a voluntary ESG Rating of Crisil ESG 61 (Strong) from Crisil ESG Ratings. No capital or business event is involved.

Business Update

Cohance Lifesciences Business Update

Cohance Lifesciences completed a USFDA inspection at its Jaggaiahpet API facility, receiving a Form 483 with five observations. The company has initiated corrective and preventive actions.

Regulatory ApprovalShalby Ltd SHALBYAlfa AlertAn Alfa Alert is ALFA Finder's top-priority alert: filings that can move a stock, such as orders, fund raises and approvals, sent to subscribers on Telegram within seconds of reaching the exchange.

Shalby Regulatory Approval

Shalby Hospital, Jabalpur received CMHO permission to resume normal operations, including patient admissions, on its previously affected floor. The hospital has now fully resumed healthcare services.

Regulatory ApprovalElantas Beck India Ltd ELANTASAlfa AlertAn Alfa Alert is ALFA Finder's top-priority alert: filings that can move a stock, such as orders, fund raises and approvals, sent to subscribers on Telegram within seconds of reaching the exchange.

Elantas Beck India Regulatory Approval

Elantas Beck India's GPCB permanently revoked the closure direction on its Ankleshwar plant. The facility can keep operating, subject to compliance conditions.

Regulatory ApprovalKalyani Cast-Tech Ltd 544023Alfa AlertAn Alfa Alert is ALFA Finder's top-priority alert: filings that can move a stock, such as orders, fund raises and approvals, sent to subscribers on Telegram within seconds of reaching the exchange.

Kalyani Cast-Tech Regulatory Approval

Kalyani Cast-Tech received RDSO Stage-I concept design approval for its new container-carrying wagon under PWDA. Stage-II detailed design approval is still required, subject to dynamics simulation conditions.

Regulatory ApprovalMukka Proteins Ltd MUKKAAlfa AlertAn Alfa Alert is ALFA Finder's top-priority alert: filings that can move a stock, such as orders, fund raises and approvals, sent to subscribers on Telegram within seconds of reaching the exchange.

Mukka Proteins Regulatory Approval

Mukka Proteins received a US FDA facility registration certificate, valid October 1, 2026 to December 31, 2027. The company says the registration supports its engagement with US customers and markets.

Execution

October 1, 2026 to December 31, 2027

Regulatory ApprovalCanara Bank CANBKAlfa AlertAn Alfa Alert is ALFA Finder's top-priority alert: filings that can move a stock, such as orders, fund raises and approvals, sent to subscribers on Telegram within seconds of reaching the exchange.

Canara Bank Regulatory Approval

Canara Bank received RBI permission to exercise the call option on its Basel III AT1 bonds (ISIN INE476A08134) of Rs.1,500 Crore. The bank is now in process of exercising the call as per the issue terms.

Value

₹1,500 Cr

Regulatory ApprovalAlembic Pharmaceuticals Ltd APLLTDAlfa AlertAn Alfa Alert is ALFA Finder's top-priority alert: filings that can move a stock, such as orders, fund raises and approvals, sent to subscribers on Telegram within seconds of reaching the exchange.

Alembic Pharmaceuticals Regulatory Approval

Alembic Pharmaceuticals received USFDA final approval for Valganciclovir for Oral Solution, 50 mg/mL. This adds to its cumulative 247 USFDA ANDA approvals.